QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine
The Open Pharmacology Journal · 2009
DOI: 10.2174/1874143600903010032 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Open Pharmacology Journal, 2009. Verfasst von Michele Schiariti und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A 59-year old woman was admitted at emergency for palpitation and dizziness. Medication history showed trimebutine 450 mg daily, because of meteorism, increased to 450 mg TID a week earlier. At admittance, sustained monomorphic ventricular tachycardia was interrupted by 100 mg intravenous lidocaine and a largely prolonged QTc (523 ± 12 ms) was seen. Discontinuation of trimebutine achieved normalisation of QTc (420 ± 10 ms, p
Zitieren
APA
Schiariti, M., Saladini, A., Placanica, A., Saolini, M., & Puddu, P. E. (2009). QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine. The Open Pharmacology Journal. https://doi.org/10.2174/1874143600903010032
Vancouver
Schiariti M, Saladini A, Placanica A, Saolini M, Puddu PE. QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine. The Open Pharmacology Journal. 2009. doi:10.2174/1874143600903010032
BibTeX
@article{Schiariti2009,
author = {Schiariti, Michele and Saladini, Angela and Placanica, Attilio and Saolini, Marta and Puddu, Paolo E.},
title = {QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine},
journal = {The Open Pharmacology Journal},
year = {2009},
doi = {10.2174/1874143600903010032}
}
EUVIMED